Trial Profile

To Assess the Safety, Reactogenicity and Immunogenicity of GSK Biologicals' Pneumococcal Conjugate Vaccine Compared to Prevenar™, Co-administered With DTPw-HBV/Hib & OPV or IPV Vaccines as a 3-dose Primary Immunization Course During the First 6 Months of Age

Status: Completed

Phase of Trial: Phase III

Latest Information Update: 05 Sep 2023

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Pneumococcal 10-valent vaccine conjugate (Primary) ; Pneumococcal 7-valent CRM197 vaccine conjugate
Indications Pneumococcal infections
Focus Pharmacodynamics; Registrational
Sponsors GlaxoSmithKline; GSK

01 Apr 2009 Results published in The Pediatric Infectious Disease Journal.
16 Oct 2008 Study start date changed from March 2006 to August March 2006, as reported by ClinicalTrials.gov.
09 Oct 2008 Study start date changed from August 2006 to March 2006, as reported by ClinicalTrials.gov.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com